VF
ACXP icon

Virtu Financial’s Acurx Pharmaceuticals ACXP Stock Holding History

Virtu Financial’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,756
Closed -$28K – 1412
2025
Q2 		$28K Buy
+2,756
New +$22.2K ﹤0.01% 1214
2025
Q1 		– Sell
-1,392
Closed -$23K – 1287
2024
Q4 		$23K Buy
+1,392
New +$41.9K ﹤0.01% 1276

Other funds holding ACXP

PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return
GWSG
GPS Wealth Strategies Group Centennial, Colorado $117M AUM 24.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Virtu Financial's ACXP Position: Q3 2025 in Review

Virtu Financial sold out of Acurx Pharmaceuticals (ACXP) in Q3 2025, closing a stake of 2,756 shares — an estimated $28K sold.

Virtu Financial first reported a position in ACXP in Q4 2024 and held it in 2 quarters. The position peaked at $28K in Q2 2025. 16 funds tracked by Wall St. Rank hold ACXP as of Q3 2025.

  • Virtu Financial reported no remaining Acurx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Virtu Financial sold 2,756 Acurx Pharmaceuticals shares in Q3 2025, an estimated $28K.
  • Virtu Financial first reported a position in Acurx Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Virtu Financial's Acurx Pharmaceuticals position peaked at $28K in Q2 2025.
  • 16 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2025.

Based on Virtu Financial's 13F filing for Q3 2025, filed 14 Nov 2025.